Table 2.

SIRs and AER for second primary malignancies among CML patients during 1992–2000 and 2002–2009

	1992–2000 Person: 4,252 Person Years: 9,849.42												2002–09 Person: 3,766 Person Years: 9,593.86
	20–49			50–69			70+			Total			20–49			50–69			70+		Total
	O	O/E	ER	O	O/E	ER	O	O/E	ER	O	O/E	ER	O	O/E	ER	O	O/E	ER	O	O/E	ER	O	O/E	ER
All sites	21	3.72#	45.19	39	0.93	−8.74	73	0.94	−15.87	133	1.06	7.69	14	2.39#	25.11	63	1.62#	72.15	96	1.32#	78.51	173	1.48#	58.21
All sites excluding non-melonoma	21	3.74#	45.29	39	0.93	−8.43	73	0.94	−14.83	133	1.06	8.15	14	2.41#	25.21	63	1.63#	72.48	96	1.33#	79.99	173	1.48#	58.82
All solid tumors	10	2.07	15.19	31	0.81	−20.76	65	0.95	−12	106	0.95	−5.68	9	1.76	11.94	54	1.53#	55.71	79	1.25	52.47	142	1.37#	39.88
Digestive system	0	0	−2.17	9	1.23	4.97	20	1.12	6.92	29	1.12	3.1	2	2.35	3.54	10	1.47	9.55	30	1.86#	46.34	42	1.77#	18.98
Respiratory system	2	4.96	4.7	8	1.16	3.29	18	1.42	17.73	28	1.4	8.19	1	3	2.05	8	1.57	8.66	15	1.21	8.63	24	1.34	6.42
Female genital	1	2.21	1.61	1	0.52	−2.69	2	0.75	−2.23	4	0.79	−1.06	2	4.6	4.82	0	0	−5.02	2	0.91	−0.63	4	0.93	−0.32
Male genital system	1	2.63	1.82	4	0.39#	−18.15	8	0.48#	−28.79	13	0.48#	−14.51	1	2.01	1.55	14	1.37	11.17	14	1.08	3.31	29	1.22	5.47
Urinary system	0	0	−0.83	3	1	−0.01	4	0.6	−8.95	7	0.7	−3.03	1	3.07	2.08	5	1.65	5.85	7	0.92	−2.04	13	1.19	2.12
Nervous System	0	0	−0.43	1	2.14	1.55	1	1.52	1.14	2	1.58	0.74	0	0	−0.43	0	0	−1.25	1	1.49	1.11	1	0.81	−0.24
Endocrine system	0	0	−0.81	0	0	−1.22	1	2.99	2.21	1	0.97	−0.03	0	0	−1.32	5	7.16#	12.81	1	1.91	1.59	6	3.63#	4.53
Lympho-hematopoietic system	11	16.06#	30.36	6	2.03	8.85	6	0.93	−1.42	23	2.28#	13.13	5	7.90#	13.45	7	2.48	12.44	9	1.31	7.06	21	2.03#	11.1
Misc.	0	0	−0.25	2	2.48	3.47	2	0.83	−1.4	4	1.21	0.7	0	0	−0.18	2	3.67	4.33	8	4.24#	20.46	10	4.01#	7.83

^# P < 0.05